Ameren Narrows FY22 EPS Guidance From $3.95-$4.15 To $4.00-$4.15 Vs $4.07 Est.
Earnings Guidance
Today, Ameren narrowed its 2022 earnings guidance range to $4.00 to $4.15 per diluted share compared to the prior range of $3.95 to $4.15 per
Ventyx Biosciences Q3 EPS $(0.59) Misses $(0.44) Estimate
Ventyx Biosciences (NASDAQ:VTYX) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.44) by 34.09 percent. This is a 81.39 percent increase over losses of $(3.17) per share
Franchise Group Sees FY22 Revenue $4.3B Vs $4.31B Est., Adj. EBITDA $350M, Adj. EPS $3.25 Vs $4.01 Est.
Outlook
Franchise Group is updating its previously announced financial outlook for fiscal year 2022. The outlook for Revenue will remain at approximately $4.3 billion, outlook for
Cambium Networks Sees Q4 Revenue $80M-$84M Vs $82.86M Est., Adj. EPS $0.23-$0.27 Vs $0.28 Est.
Fourth Quarter 2022 Financial Outlook
Taking into account our current visibility, the financial outlook as of November 3, 2022, for the fourth
BiondVax Provides Plan To Address Nasdaq Compliance
BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing, and commercializing innovative products for the prevention and treatment of
Axcelis Technologies Q3 EPS $1.21 Beats $1.13 Estimate, Sales $229.18M Beat $224.38M Estimate
Axcelis Technologies (NASDAQ:ACLS) reported quarterly earnings of $1.21 per share which beat the analyst consensus estimate of $1.13 by 7.08 percent. This is a 49.38 percent increase over earnings of $0.81 per share from
Greenlight Capital Re Q3 EPS $(0.56)
Greenlight Capital Re (NASDAQ:GLRE) reported quarterly losses of $(0.56) per share which missed the analyst consensus estimate of $0.05 by 1220 percent. This is a 33.33 percent decrease over losses of $(0.42) per share
Albemarle Revises FY22 Sales Guidance From $7.1B-$7.5B To $7.1B-$7.4B Vs $7.51B Est., Revises EPS Guidance From $19.25-$22.25 To $19.75-$21.75 Vs $21.28 Est.
Outlook
Full-year 2022 outlook remains strong, with net sales expected to be more than double and adjusted EBITDA expected to be nearly four times 2021 results. Ongoing strength in lithium pricing and end
Albemarle Q3 Adj. EPS $7.50 Beats $6.97 Estimate, Sales $2.09B Miss $2.25B Estimate
Albemarle (NYSE:ALB) reported quarterly earnings of $7.50 per share which beat the analyst consensus estimate of $6.97 by 7.6 percent. This is a 614.29 percent increase over earnings of $1.05 per share from the same
Maravai LifeSciences Q3 Adj. EPS $0.37 Beats $0.33 Estimate, Sales $191.26M Miss $195.10M Estimate
Maravai LifeSciences (NASDAQ:MRVI) reported quarterly earnings of $0.37 per share which beat the analyst consensus estimate of $0.33 by 12.12 percent. This is a 15.91 percent decrease over earnings of $0.44 per share